Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Perri M, Caroleo MC, Liu N et al. 9-cis retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models. Exp. Cell. Res. 354(1), 25–30 (2017).
  Medline CASGoogle Scholar
• 2 Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochem. J. 466(2), 203–218 (2015).
  Medline CASGoogle Scholar
• 3 Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 48(3), e219 (2016).
  Medline CASGoogle Scholar
• 4 Paulweber B, Valensi P, Lindström J et al. A European evidence-based guideline for the prevention of Type 2 diabetes. Horm. Metab. Res. 42(1), S3–S36 (2010).
  Medline CASGoogle Scholar
• 5 Aschner PM, Muñoz OM, Girón D et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow-up of Type 2 diabetes mellitus in adults. Colomb. Med. (Cali.) 47(2), 109–131 (2016).
  MedlineGoogle Scholar
• 6 Siavash M, Tabbakhian M, Sabzghabaee AM, Razavi N. Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in Type 2 diabetes mellitus patients. J. Res. Pharm. Pract. 6(2), 73–76 (2017).
  Medline CASGoogle Scholar
• 7 Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction? Curr. Drug Saf. doi:10.2174/1574886311666160405110515 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 8 Chaudhury A, Duvoor C, Reddy Dendi VS et al. Clinical review of antidiabetic drugs: implications for Type 2 diabetes mellitus management. Front. Endocrinol. 8, 6 (2017). • Describes Type 2 diabetes mellitus and its therapies.
  MedlineGoogle Scholar
• 9 Vinayagam R, Xiao J, Xu B. An insight into anti-diabetic properties of dietary phytochemicals. Phytochem. Rev. 16(3), 535–553 (2017).
  CASGoogle Scholar
• 10 Carullo G, Cappello AR, Frattaruolo L, Badolato M, Armentano B, Aiello F. Quercetin and derivatives: useful tools in inflammation and pain management. Future Med. Chem. 9(1), 79–93 (2017).
  CASGoogle Scholar
• 11 D’Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 106, 256–271 (2015).
  MedlineGoogle Scholar
• 12 Vinayagam R, Xu B. Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr. Metab. 12, 60 (2015).
  Google Scholar
• 13 Wach A, Pyrzyńska K, Biesaga M. Quercetin content in some food and herbal samples. Food Chem. 100(2), 699–704 (2007). •• Quercetin in diabetes: various relevant data.
  CASGoogle Scholar
• 14 Mukhopadhyay P, Prajapati AK. Quercetin in anti-diabetic research and strategies for improved quercetin bioavailability using polymer-based carriers – a review. RSC Adv. 5, 97547–97562 (2015).
  CASGoogle Scholar
• 15 Pilichiewicz A, O’Donovan D, Feinle C et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88(8), 3829–3834 (2003).
  Medline CASGoogle Scholar
• 16 Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. Curr. Pharm. Des. 17(8), 769–777 (2011).
  Medline CASGoogle Scholar
• 17 Boskou D, Blekas G, Tsimidou M. Olive oil composition. In: Olive Oil Chemistry and Technology (2nd Edition). Boskou D (Ed.). Elsevier: Academic Press and AOCS Press, Amsterdam, the Netherlands, 282 (2006).
  Google Scholar
• 18 Santos LRB, Rebelato E, Graciano MFR, Abdulkader F, Curi R, Carpinelli AR. Oleic acid modulates metabolic substrate channeling during glucose-stimulated insulin secretion via NAD(P)H oxidase. Endocrinology 152(10), 3614–3621 (2011).
  Medline CASGoogle Scholar
• 19 Ferdaoussi M, Bergeron V, Zarrouki B et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55(10), 2682–2692 (2012).
  Medline CASGoogle Scholar
• 20 McKillop AM, Moran BM, Abdel-Wahab YHA, Flatt PR. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br. J. Pharmacol. 170(5), 978–990 (2013).
  Medline CASGoogle Scholar
• 21 Liu B, Hassan Z, Amisten S et al. The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis. Diabetologia 56(11), 2467–2476 (2013).
  Medline CASGoogle Scholar
• 22 Barton M, Prossnitz ER. Emerging roles of GPER in diabetes and atherosclerosis. Trends Endocrinol. Metab. 26(4), 185–192 (2015).
  Medline CASGoogle Scholar
• 23 Tiano JP, Delghingaro-Augusto V, Le May C et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β-cell failure in rodent models of Type 2 diabetes. J. Clin. Invest. 121(8), 3331–3342 (2011).
  Medline CASGoogle Scholar
• 24 Aiello F, Carullo G, Giordano F et al. Identification of breast cancer inhibitors specific for G protein-coupled estrogen receptor (GPER)-expressing cells. ChemMedChem 12, 1–8 (2017).
  Google Scholar
• 25 Itoh Y, Kawamata Y, Harada M et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422, 173–176 (2003). •• Fatty acids and G protein-coupled receptors (GPRs): an insight into diabetes.
  Medline CASGoogle Scholar
• 26 Schnell S, Schaefer M, Schöfl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β cells through activation of GPR40. Mol. Cell. Endocrinol. 263, 173–180 (2007).
  Medline CASGoogle Scholar
• 27 Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 340, 483–489 (2012).
  Medline CASGoogle Scholar
• 28 Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with Type 2 diabetes. Diabetes Obes. Metab. 14, 271–278 (2012).
  Medline CASGoogle Scholar
• 29 Srivastava A, Yano J, Hirozane Y et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124–127 (2014).
  Medline CASGoogle Scholar
• 30 Chen C, Li H, Long Y. GPR40 agonists for the treatment of Type 2 diabetes mellitus: The biological characteristics and the chemical space. Bioorg. Med. Chem. Lett. 26(23), 5603–5612 (2016).
  Medline CASGoogle Scholar
• 31 Li H, Huang Q, Chen C, Xu B, Wang H. Long Y discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold. J. Med. Chem. 60, 2697–2717 (2017).
  Medline CASGoogle Scholar
• 32 Jurica EA, Wu X, Williams KN et al. Discovery of pyrrolidine-containing GPR40 agonists: stereochemistry effects a change in binding mode. J. Med. Chem. 60, 1417–1431 (2017).
  Medline CASGoogle Scholar
• 33 Yang J, Li Z, Li H et al. Design, synthesis and structure–activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker. Bioorg. Med. Chem. 25, 2445–2450 (2017).
  Medline CASGoogle Scholar
• 34 Krasavin M, Lukin A, Bagnyukova D et al. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835. Bioorg. Med. Chem. 24, 5481–5494 (2016).
  Medline CASGoogle Scholar
• 35 Krasavin M, Lukin A, Zhurilo A et al. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. Bioorg. Med. Chem. 24, 2954–2963 (2016).
  Medline CASGoogle Scholar
• 36 Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg. Med. Chem. Lett. 24, 2991–3000 (2014).
  Medline CASGoogle Scholar
• 37 Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, Hudson BD. Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br. J. Pharmacol. 172, 3254–3265 (2015).
  Medline CASGoogle Scholar
• 38 Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of Type 2 diabetes by free fatty acid receptor agonists. Front. Endocrinol. 5, 137 (2014). •• TAK-875 and other GPR40 synthetic ligands.
  MedlineGoogle Scholar
• 39 Lin DCH, Guo Q, Luo J et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. J. Mol. Pharm. 82, 843–859 (2012).
  Medline CASGoogle Scholar
• 40 Christiansen E, Watterson KR, Stocker CJ et al. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br. J. Nutr. 113, 1677–1688 (2015).
  Medline CASGoogle Scholar
• 41 Tikhonova IG, Poerio E. Free fatty acid receptors: structural models and elucidation of ligand binding interactions. BMC Struct. Biol. 15, 16 (2015).
  MedlineGoogle Scholar
• 42 Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet β cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 289(4), E670–E677 (2005). •• GPR40 flat structure–activity relationships.
  Medline CASGoogle Scholar
• 43 Elias S, Wisam S, Luai A, Massad B, Nimer A. Lipotoxicity in obesity: benefit of olive oil. In: Obesity and Lipotoxicity, Advances in Experimental Medicine and Biology 960. Engin AB, Engin A (Eds.), Springer International Publishing AG, Gewerbestrasse, Switzerland (2017).
  Google Scholar
• 44 Youl E, Bardy G, Magous R et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic β cells against oxidative damage via the ERK1/2 pathway. Br. J. Pharmacol. 161, 799–814 (2010). •• Oleic acid: why do we use it?
  Medline CASGoogle Scholar
• 45 Kim MK, Park K, Lee C, Park HR, Choo Hyunah, Chong Y. Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoiety. J. Med. Chem. 53, 8597–8607 (2010).
  Medline CASGoogle Scholar
• 46 Zhou A, Kikandi S, Sadik OA. Electrochemical degradation of quercetin: isolation and structural elucidation of the degradation products. Electrochem. Commun. 9, 2246–2255 (2007).
  CASGoogle Scholar
• 47 Trouillas P, Marsal P, Siri D, Lazzaroni R, Duroux J. A DFT study of the reactivity of OH groups in quercetin and taxifolin antioxidants: the specificity of the 3-OH site. Food Chem. 97, 679–688 (2006).
  CASGoogle Scholar
• 48 Saija A, Tomaino A, Trombetta D et al. ‘In vitro’ antioxidant and photoprotective properties and interaction with model membranes of three new quercetin esters. Eur. J. Pharm. Biopharm. 56, 167–174 (2003).
  Medline CASGoogle Scholar
• 49 Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49(3), 424–430 (2000).
  Medline CASGoogle Scholar
• 50 Hectors TLM, Vanparys C, Pereira-Fernandes A, Martens GA, Blust R. Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function. PLoS ONE 8(3), e60030 (2013).
  Medline CASGoogle Scholar
• 51 Kane MA, Folias AE, Pingitore A et al. Identification of 9-cis-retinoic acid as a pancreas-specific autacoid that attenuates glucose-stimulated insulin secretion. Proc. Natl Acad. Sci. USA 107(50), 21884–21889 (2010). •• Limitations of quercetin and valorization of our hybrid molecule.
  Medline CASGoogle Scholar
• 52 Li N, Shi Z, Tang Y, Yang J, Duan J. An efficient partial synthesis of 4′-O-methylquercetin via regioselective protection and alkylation of quercetin. Beilstein J. Org. Chem. 5, 60 (2009).
  MedlineGoogle Scholar
• 53 Schrödinger, LLC, www.schrodinger.com
  Google Scholar
• 54 Montana E, Bonner-Weir S, Weir GC. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J. Clin. Invest. 91, 780 (1993).
  Medline CASGoogle Scholar
• 55 Mainini F, Contini A, Nava D et al. Synthesis, molecular characterization and preliminary antioxidant activity evaluation of quercetin fatty esters. J. Am. Oil. Chem. Soc. 90, 1751–1759 (2013). • Chemical synthesis and biological methods.
  CASGoogle Scholar
• 56 McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42, 128–138 (1999).
  Medline CASGoogle Scholar
• 57 Bardy G, Virsolvy A, Quignard JF et al. Quercetin induces insulin secretion by direct activation of L-type calcium channels in pancreatic beta cells. Br. J. Pharmacol. 169, 1102–1113 (2013).
  Medline CASGoogle Scholar
• 58 Zhang Y, Meifang X, Niu G, Tan H. Mechanisms of oleic acid deterioration in insulin secretion: role in the pathogenesis of Type 2 diabetes. Life Sci. 77(17), 2071–2081 (2005).
  Medline CASGoogle Scholar
• 59 Biasutto L, Marotta E, De Marchi U, Zoratti M, Paradisi C. Ester-based precursors to increase the bioavailability of quercetin. J. Med. Chem. 50, 241–253 (2007).
  Medline CASGoogle Scholar
• 60 Shia C, Tsai S, Kuo S, Hou Y, Lee Chao P. Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J. Agric. Food Chem. 57, 83–89 (2009).
  Medline CASGoogle Scholar
• 61 Chen Y, Xiao P, Ou-Yang D et al. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin. Exp. Pharmacol. Physiol. 36(8), 828–833 (2009). • About metabolism of quercetin.
  Medline CASGoogle Scholar